Clinical Trials Browser

Active not recruiting × Vorinostat × 90 days × Clear all

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00336063 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Phase 1 Active not recruiting

18 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT00392353 2026-04-13

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 1/2 Active not recruiting

135 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01587352 2026-04-13

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Active not recruiting

40 enrolled

Dermatologic

Uveal Melanoma

NCT01522976 2026-03-31

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2 Active not recruiting

282 enrolled 11 charts

Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01297764 2026-03-23

QUAD

Phase 1/2 Active not recruiting

17 enrolled

Plasma cell

Multiple Myeloma

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

28 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT00616967 2026-03-05

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Phase 2 Active not recruiting

68 enrolled 17 charts

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT03842696 2026-01-27

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Phase 1/2 Active not recruiting

43 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Graft vs Host Disease, Hematologic Diseases, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

QUAD

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation